
Submission sought on MoH review
The Ministry of Health (MoH) is reviewing the regulation of the New Zealand health workforce and is asking for submissions.

The Ministry of Health (MoH) is reviewing the regulation of the New Zealand health workforce and is asking for submissions.

A Moorfields-led team improved the visual acuity (VA) in children with retinal dystrophy caused by a genetic deficiency of AIPL1, using a viral vector to deliver healthy copies of the gene to their re

SpliceBio, a clinical-stage genetic medicine company pioneering protein splicing, has dosed the first patient in the phase 1/2 ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector for the

With waiting lists growing, Drew Jones delves into the factors affecting cataract surgery efficiency

Luxa Biotechnology announced trial results showing substantial improvements in best corrected visual acuity (BCVA) for patients receiving its novel adult retinal pigment epithelial stem cell therapy (

Neurotech Pharmaceuticals announced its Encelto (revakinagene taroretcel-lwey) implant has become the first US Food and Drug Administration (FDA)-approved therapy to slow macular telangiectasia (MacTe

Prof Helen Danesh-Meyer CNZM is the first New Zealander to be appointed president of the Neuro-Ophthalmology Society of Australia (NOSA).

An international team led by New Zealand researchers found patients with type-1 diabetes had stable or improved diabetic retinopathy (DR) after using automated insulin delivery (AID) for at least six months.

New Zealand distributor Toomac Ophthalmic confirms Bausch + Lomb’s 27 March 2025 voluntary recall only concerns the enVista Envy intraocular lens (IOL) in this market.

A University of Sydney literature review found topical cyclosporine (CsA) treatment may be superior to the vehicle, artificial tears (AT) or other topical treatment alternatives for ocular surface dis

US researchers who found vascular endothelial growth factor (VEGF) played a critical role in melanoma cells metastasising to organs outside the eye are trialling a new drug to prevent it. Using an o

Medsafe hasn’t yet received an application for the approval of geographic atrophy (GA) treatment Syfovre in New Zealand, despite its recent approval in Australia. In two studies published in 2023, i